OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
2025.Mar.03
Corporate
OBI Pharma Invited to Host Workshop at World ADC London
Sharing ADC Development Insights and Unveiling Linker Technology Details for the First Time
2025.Mar.02
Corporate
OBI Pharma's GlycOBI® Platform Gains Attention at Nanjing Summit
Optimized Process Design and CMC: Key to Next-Generation ADC Development
2025.Feb.20
Corporate
OBI Pharma Showcases Proprietary ADC Platform GlycOBI® in China
Drawing Strong Industry Interest
2025.Feb.19
Corporate
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
2024.Dec.31
Corporate
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
2024.Dec.23
Corporate
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
2024.Dec.11
Sustainability
Award & Certification
OBI Pharma Earns Sports Enterprise Certification Again
Building a Healthy Workplace and Fulfilling Sustainability Commitments
2024.Dec.02
Corporate
Key Technologies + Innovative Products + Flexible Business Models
Dr. Heidi Wang: Shaping OBI Pharma into a Leading and Thriving Global Biotech Company
2024.Nov.14
Corporate
OBI Pharma Showcases Biomarker Innovations at Singapore APAC Summit
Precision Medicine Tools Drive Success in New Drug Development